SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Healthpeak Properties, Inc. (DOC) trades at a trailing P/E of 161.0, forward P/E of 70.7. Trailing earnings yield is 0.62%, forward earnings yield 1.41%. PEG 0.51 (Peter Lynch undervalued ≤1.0). Graham Number is $5.25.
Criteria proven by this page:
- VALUE (42/100, Partial) — mixed signals — some valuation metrics are favorable while others are stretched.
- Forward P/E 70.7 (down from trailing 161.0) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.51 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 0.62% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 1.41% as earnings recover.
- Analyst consensus target $18.00 (+6.7% upside) — modest upside expected.
Overall SharesGrow Score: 57/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
~
VALUE
42/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — DOC
Valuation Multiples
P/E (TTM)161.0
Forward P/E70.7
PEG Ratio0.51
Forward PEG0.51
P/B Ratio1.53
P/S Ratio4.07
EV/EBITDA13.3
Per Share Data
EPS (TTM)$0.10
Forward EPS (Est.)$0.24
Book Value / Share$11.93
Revenue / Share$4.06
FCF / Share$1.68
Yields & Fair Value
Earnings Yield0.62%
Forward Earnings Yield1.41%
Dividend Yield7.39%
Graham Number$5.25
SharesGrow IV$28.42 (+68.4%)
Analyst Target$18.00 (+6.7%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
22.1 |
-0.10 |
7.99 |
6.52 |
7.05% |
| 2017 |
29.5 |
-0.86 |
4.94 |
6.61 |
5.68% |
| 2018 |
12.4 |
0.08 |
5.52 |
11.03 |
5.30% |
| 2019 |
368.1 |
-3.83 |
2.75 |
13.51 |
4.30% |
| 2020 |
38.8 |
0.05 |
2.38 |
9.75 |
4.91% |
| 2021 |
38.5 |
1.85 |
2.99 |
10.26 |
3.34% |
| 2022 |
27.0 |
-25.10 |
2.03 |
6.55 |
4.80% |
| 2023 |
35.4 |
-0.90 |
1.71 |
4.97 |
6.07% |
| 2024 |
56.3 |
-1.58 |
1.63 |
5.07 |
5.80% |
| 2025 |
156.9 |
-2.17 |
1.49 |
3.97 |
7.59% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$0.22 |
$241.03M |
$29.98M |
12.4% |
| 2017 |
$0.23 |
$343.58M |
$38.15M |
11.1% |
| 2018 |
$0.30 |
$422.55M |
$56.23M |
13.3% |
| 2019 |
$0.02 |
$415.28M |
$9.49M |
2.3% |
| 2020 |
$0.02 |
$437.51M |
$10.2M |
2.3% |
| 2021 |
$0.05 |
$457.7M |
$25.4M |
5.5% |
| 2022 |
$0.07 |
$526.64M |
$37.8M |
7.2% |
| 2023 |
$0.56 |
$2.18B |
$306.01M |
14% |
| 2024 |
$0.36 |
$2.7B |
$243.14M |
9% |
| 2025 |
$0.10 |
$2.82B |
$71.35M |
2.5% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$0.24 |
$0.23 – $0.25 |
$2.79B |
$2.56B – $2.88B |
3 |
| 2027 |
$0.29 |
$0.27 – $0.30 |
$2.91B |
$2.65B – $3.03B |
4 |
| 2028 |
$0.31 |
$0.28 – $0.32 |
$3.13B |
$2.93B – $3.25B |
3 |
